Cantor Fitzgerald Lifts Earnings Estimates for NeuroPace

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings estimate for NeuroPace, projecting a loss of ($0.83) per share, improved from the earlier estimate of ($0.87).
• NeuroPace reported quarterly earnings of ($0.26) per share, missing analyst estimates, but exceeded revenue expectations with $23.52 million in revenue.
• NeuroPace maintains a consensus rating of "Buy" from analysts, with target prices ranging from $15.00 to $18.00 following various research reports.

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Equities researchers at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of NeuroPace in a research report issued to clients and investors on Wednesday, August 13th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings per share of ($0.83) for the year, up from their prior forecast of ($0.87). Cantor Fitzgerald has a "Overweight" rating and a $17.00 price target on the stock. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The firm had revenue of $23.52 million during the quarter, compared to analyst estimates of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%.

NPCE has been the subject of several other research reports. HC Wainwright started coverage on shares of NeuroPace in a research note on Wednesday, May 28th. They issued a "buy" rating and a $18.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on shares of NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 14th. Finally, Wells Fargo & Company lowered their price objective on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating for the company in a research note on Wednesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, NeuroPace presently has a consensus rating of "Buy" and a consensus price target of $16.60.

NeuroPace Trading Up 1.1%

Shares of NASDAQ NPCE traded up $0.10 during midday trading on Friday, reaching $9.13. The stock had a trading volume of 18,223 shares, compared to its average volume of 274,604. The firm has a market cap of $301.86 million, a price-to-earnings ratio of -10.81 and a beta of 1.89. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.98. The company has a debt-to-equity ratio of 3.02, a quick ratio of 5.70 and a current ratio of 5.47. The company's 50 day moving average price is $10.00 and its 200 day moving average price is $11.78.

Institutional Trading of NeuroPace

Hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. boosted its holdings in NeuroPace by 83.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company's stock worth $27,000 after acquiring an additional 1,118 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in NeuroPace during the 4th quarter worth $29,000. Legal & General Group Plc boosted its holdings in NeuroPace by 86.0% during the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock worth $30,000 after acquiring an additional 1,239 shares during the last quarter. Quantbot Technologies LP purchased a new position in NeuroPace during the 2nd quarter worth $35,000. Finally, GAMMA Investing LLC purchased a new position in NeuroPace during the 1st quarter worth $53,000. Institutional investors and hedge funds own 78.83% of the company's stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.